TAGCyx has executed a collaborative antibody-aptamer conjugate research agreement with Chiome Bioscience Inc.
TAGCyx has signed collaborative research agreement with Chiome Bioscience Inc. (CEO: Shigeru Kobayashi, Head office: Tokyo, listed on Tokyo Stock Exchange Mothers Index: 4583) in relation to innovative aptamer therapeutics.
TAGCyx possesses a leading, proprietary, artificial nucleic acid base pair technology (Xenoligo), producing high affinity and selective DNA aptamers “Xenoligo®”, whereas Chiome is pursuing development of unique therapeutic monoclonal antibody(ies).
Conjugating Xenoligo with Chiome’s monoclonal antibodies will generate bispecific molecules that have the potential to further enhance the functionality of potential therapeutic agents.
Dr Chizuko Koseki, Chief Executive Officer of TAGCyx added “we are pleased to enter into a collaboration with Chiome, bringing together 2 leading technologies to potentially enhance therapeutic research”